Printer Friendly

INVESTIGATORS TO PRESENT CLINICAL EFFICACY AND SAFETY DATA FOR ABLC AT ICAAC CONFERENCE; SAFETY DATA STATISTICALLY SIGNIFICANT

 PRINCETON, N.J., Sept. 21 /PRNewswire/ -- At a meeting of investment analysts held at the Company's headquarters in Princeton, N.J., The Liposome Company, Inc. (Nasdaq: LIPO and LIPOZ) announced that investigators will present a poster on October 7 at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference. In the abstract, 69 percent of 183 patients all of whom had previously failed treatment with conventional amphotericin and/or other systemic antifungal drugs responded to treatment with ABLC(R), the Company's novel, proprietary agent for the treatment of severe, systemic fungal infections. ABLC(R) is currently in Phase III clinical trials in the United States for the treatment of aspergillosis refractory to amphotericin B and the empiric therapy of suspected fungal infections in immunocompromised patients undergoing chemotherapy. Marketing applications have been filed for ABLC(R) in eight European countries. The investigators also reported a statistically significant improvement in kidney function in patients who had suffered nephrotoxicity, induced by the prior administration of free amphotericin B. Renal damage is a major, dose limiting toxicity of free amphotericin B.
 In a separate poster also to be presented at ICAAC, investigators will present results of patients suffering from life threatening fusariosis, an often fatal fungal infection. Of the eight patients studied, there was an 87.5 percent clinical response. These patients had previously failed conventional therapy either because of a lack of efficacy or toxicity.
 Charles A. Baker, Chairman and Chief Executive Officer, and other members of management updated analysts on the status of the Company's products. In Europe, marketing applications have been filed for ABLC(R) in eight countries and an additional ten applications are expected to be filed during the remainder of 1994. In the U.S., the Company has commenced two Phase III clinical trials for ABLC(R). The first is for the use of ABLC(R) for the treatment of patients with aspergillosis refractory to amphotericin B. The second trial is a randomized, comparative trial of ABLC(R) versus conventional amphotericin for the first line empiric therapy of suspected fungal infections in immunocompromised patients receiving cancer chemotherapy or bone marrow transplants. The Company has treated over 1,000 patients with ABLC(R) in clinical trials as well as emergency use protocols in both the U.S. and Europe.
 In a presentation outlining international commercialization activities for ABLC(R), the Company announced that it is conducting discussions with third parties to co-promote ABLC(R) in certain targeted countries.
 At the annual meeting of the American Society of Clinical Oncology (ASCO) in May 1994, investigators from the M.D. Anderson Cancer Center in Houston reported preliminary results of a Phase II trial showing that 69.5 percent of patients with metastatic breast cancer responded to treatment with TLC D-99 (liposomal doxorubicin) in combination with two other commonly used anti-cancer drugs. The investigators concluded that the preliminary data showed that the treatment regimen has significant antitumor activity in metastatic breast cancer and that the liposomal encapsulation of doxorubicin appears to permit administration of a higher cumulative dose.
 The Company also reviewed clinical data that was presented at the Seventh World Conference on Lung Cancer in June 1994. Investigators at the Dana-Farber Institute/Harvard Medical School presented data from a Phase I clinical trial of a very high dose (up to 165 mg/meter squared) of TLC D-99. Although the trial was designed to test the safety of TLC D-99 in high doses, clinical responses were recorded in three of ten patients with non-small cell lung cancer (NSCLC) and two of two patients with mesothelioma. These cancers historically have a very low response rate to chemotherapy.
 Separately, the Company disclosed that it expects pivotal Phase III clinical trials for TLC D-99 to commence in the fourth quarter of 1994.
 The Company also presented preclinical data for TLC C-53, liposomal prostaglandin E1, demonstrating results in several preclinical models, including its effectiveness in a model where TLC C-53 was able to rescue animals from endotoxin shock as late as 16 hours following the administration of endotoxin. In addition, TLC C-53 is currently being tested in a Phase I/II clinical trial of Acute Respiratory Distress Syndrome (ARDS). Twenty-three of a targeted twenty-four patients have been enrolled in the study. The Company is planning to start additional Phase II trials in acute myocardial infarction, sepsis induced SIRS (systemic inflammatory response syndrome) and trauma induced SIRS.
 The Company outlined the clinical status of TLC A-60, a novel vaccine adjuvant that is currently being tested by a partner in an influenza vaccine. Patient accrual in a Phase II study is nearing completion and, if Phase II has positive results, the Company expects that a Phase III trial would be conducted in 1995.
 In a review of the Company's research activities, the Company discussed its programs to develop additional agents to treat various cancers and presented in vitro and in vivo data on the efficacy of several novel compounds. The in vitro data on one compound included effectiveness in a multiple drug resistant cell line. The Company also reviewed progress in developing a separate form of liposomal prostaglandin E1, TLC C-54, that has potential applications as a treatment for rheumatoid arthritis and lupus. Data presented included the demonstration of inhibition of progression of arthritis in a preclinical model and inhibition of vasculitis and resulting skin lesions in a model of systemic lupus erythematosis.
 In summarizing the meeting Mr. Baker said, "I am pleased with the progress we have made and with the exciting clinical results that our products have demonstrated. We are aggressively developing our products and, with our significant cash reserves, have the capability and flexibility to rapidly and thoroughly continue our commercialization programs."
 The Liposome Company is a leading company dedicated to the development of liposome and lipid-based pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases. The Company has filed applications to market ABLC(R) in Europe and is conducting Phase III studies for the treatment of systemic fungal infections in the U.S.; TLC D-99 will be starting Phase III trials for the treatment of metastatic breast cancer; TLC A-60 is in Phase II trials as a liposomal adjuvant to be used in an influenza virus vaccine; TLC C-53 is currently in Phase I/II trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) in the U.S. and has completed Phase I trials for Systemic Inflammatory Response Syndrome (SIRS) in Europe.
 -0- 9/21/94
 /CONTACT: Brooks Boveroux, Vice President, Finance and Chief Financial Officer of The Liposome Company, Inc., 609-452-7060/
 (LIPO)


CO: Liposome Company, Inc. ST: New Jersey IN: MTC SU:

TW -- NY037 -- 6383 09/21/94 11:02 EDT
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 21, 1994
Words:1110
Previous Article:POWER AUTHORITY AWARDS POWER FOR LOG HOME KIT MAKER
Next Article:GOLDEN TRIANGLE ROYALTY & OIL, INC. ANNOUNCES ACQUISITIONS
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters